Untangling the immunological implications of Nadir on CD4+ cell recovery during suppressive highly active antiretroviral therapy

Clinical Infectious Diseases

Volumn 46, Issue 1, 2008, Pages 149-150

  Ferraris, Laurenzia ^a   Bellistri, Giusi Maria ^b   Pegorer, Valentina ^b   Tincati, Camilla ^b   Meroni, Luca ^a   Galli, Massimo ^a   Monforte, Antonella D'Arminio ^b   Gori, Andrea ^c   Marchetti, Giulia ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR ALPHA;

CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; TREATMENT OUTCOME;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HOMEOSTASIS; HUMANS;

EID: 39349114367     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/524087     Document Type: Letter

References (10)

1. + cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007; 44:441-6.
2. Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic reasponse after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000; 133:401-10.
3. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-29.
4. Florence E, Lundgren J, Dreezen C, et al. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med 2003; 4:255-62.
5. Kaufmann GR, Furrer H, Ledergerber B, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005; 41:361-72.
6. Anthony KB, Yoder C, Metcalf JA, et al. Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. J Acquir Immune Defic Syndr 2003; 33:125-33.
7. Benveniste O, Flahault A, Rollot F, et al. Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. J Infect Dis 2005; 191:1670-9.
8. Marchetti G, Gori A, Casabianca A, et al. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. AIDS 2006; 20:1727-36.
9. Alves NL, Arosa FA, van Lier RA. Common gamma chain cytokines: dissidence in the details. Immunol Lett 2007; 108:113-20.
10. Fry T, Mackall C. Interleukin-7: from bench to clinic. Blood 2002; 99:3892-904.